Dr. Choueiri on the Role of Cabozantinib in RCC

Toni Choueiri, MD
Published: Tuesday, Oct 10, 2017



Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma (RCC).

There is potential for cabozantinib to be an option in the frontline setting for patients with RCC, states Choueiri.In the results of the phase II CABOSUN trial, cabozantinib showed superiority in progression-free survival (PFS).

It could become an option for patients with intermediate and poor-risk RCC that are completely untreated and systemic therapy naïve, explains Choueiri.
 


Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma (RCC).

There is potential for cabozantinib to be an option in the frontline setting for patients with RCC, states Choueiri.In the results of the phase II CABOSUN trial, cabozantinib showed superiority in progression-free survival (PFS).

It could become an option for patients with intermediate and poor-risk RCC that are completely untreated and systemic therapy naïve, explains Choueiri.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x